Nonetheless, a resistance to osimertinib is emerging, and an evaluation of the distinct on- and off-target MOR to EGFR TKI via NGS-based liquid biopsies is urgently needed to effectively treat osimertinib-resistant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.